Image default
Water News

AstraZeneca gets DCGI nod for asthma drug

NEW DELHI: Drug firmAstraZenecaIndia on Tuesday said it has received marketing authorisation for anasthma drugfrom theDrugs Controller General of India(DCGI).

The company has received approval from the DCGI for Fasenra (Benralizumab solution for injection in a single dose prefilled syringe30 mg/ml) for patients with severe asthma (eosinophilic asthma), AstraZeneca India said in a statement.

Benralizumab (Fasenra) is indicated as an add-on treatment for severe asthma with an eosinophilic phenotype in adult patients, it added.

“The drug firm has always been at the forefront of innovative solutions for non-communicable diseases. Despite currently available therapies, a significant unmet need for effective management of severe Asthma continues to exist globally as well as in India,” AstraZeneca India Managing Director Gagandeep Singh Bedi said.

The regulatory approval of Fasenra in India will provide better medicine for the management of eosinophilic asthma and support patients to attain a better quality of life, he added.

(Catch all theBusiness News,Breaking NewsEvents andLatest NewsUpdates onThe Economic Times.)

Download The Economic Times News App to get Daily Market Updates & Live Business News.


Related posts

Subpolar marginal seas play a key role in making the subarctic Pacific nutrient-rich


AstraZeneca Pharma | DCGI: AstraZeneca Pharma gets DCGI nod to market asthma drug


Aerodynamicists reveal link between fish scales and aircraft drag


Leave a Comment